drugset / Trial / NCT03090165
Ribociclib and Bicalutamide in AR+ TNBC
Phase 1/2
Active not recruiting
37 enrolled
Kari Wisinski
Big Ten Cancer Research Consortium · collabNovartis · collabUniversity of Wisconsin, Madison · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is involved.
Timeline
- Start
- 2018-05-07
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | 150 mg | Oral |
| Subject | Ribociclib | Small molecule | 400 mg | Oral |
| Subject | Ribociclib | Small molecule | 600 mg | Oral |